To observe the clinical effects of Tongxinluo Capsule in the treatment of patients with intracranial atherosclerosis and its influence on disease-related indexes of patients.Methods:A total of 200 patients with intracranial atherosclerosis admitted in Hebei Yiling Hospital from Jan.2017 to Nov.2018 were randomly divided into a control group and an observation group according to random number table，with 100 cases in each group.Both groups were given routine treatment，and the observation group was given Tongxinluo Capsule for the treatment.Before and after treatment，graded composition of intracranial artery stenosis，lipid metabolism，coagulation function，intracranial hemodynamics and levels of cytokines were compared between the 2 groups.The adverse events of cardiovascular and cerebrovascular diseases and rate of adverse drug reactions were compared between the 2 groups.Results:After treatment，the rate of slight stenosis of intracranial artery，TC，LDL，TG，HDL，PT，APTT，TT，FIB，Vs，Vd，VM，PI，SI，S/D，IL-6，TNF-α，hs CRP in the 2 groups were higher than those in the control group，and the rate of cardiovascular and cerebrovascular adverse events in the observation group was lower than that in the control group(P<0.05).Conclusion:Tongxinluo Capsule can effectively reduce the degree of intracranial artery stenosis and has high safety，which may be related to the improvement of lipid metabolism，coagulation function and inflammatory state of Tongxinluo Capsule.